Digi Expands IoT Solutions for Medical, Smart Energy and Industrial Sectors with Newest Addition to the MP1 Family of System-On-Modules
13.3.2023 11:00:00 EET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, and an ST Authorized Partner, today unveiled Digi ConnectCore® MP13, the newest member of its Digi ConnectCore® MP1 family of system-on-modules (SOMs) designed for longevity, scalability and demanding product lifecycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005132/en/
Digi ConnectCore MP13 System-on-Module unveiled at Embedded World 2023 (Graphic: Business Wire)
A compact, wireless and secure system-on-module based on the STMicroelectronics STM32MP133C MPU, Digi ConnectCore MP13 is among the industry’s smallest SOMs with pre-certified Wi-Fi 5 and Bluetooth® 5.2. This solution delivers cost-effective, flexible and reliable connectivity for original equipment manufacturers (OEMs) looking to reduce risk and product development efforts, while accelerating overall time to market of applications for the medical, smart energy and industrial sectors.
Complete with embedded security framework, Digi TrustFence®, and Digi Embedded Yocto Linux® software support, Digi ConnectCore MP13 SOMs eliminate implementation barriers and offer exceptional design flexibility for both complex and simple applications thanks to the unique and compact Digi SMTplus® surface-mount form factor (29x29 mm) — making them ideal for medical devices, industrial gateways, environmental test equipment, renewable-energy controllers and EV charging stations.
“We are delighted to expand the Digi ConnectCore MP1 family of SOMs and continue our commitment to providing off-the-shelf, wireless-enabled solutions suitable for a broad range of applications,” said Andreas Burghart, Senior Product Manager at Digi. “Designed for longevity, scalability and demanding 10+ year product lifecycles, Digi ConnectCore MP13 is a well-suited addition to our complete ecosystem of hardware, software and services that help manufacturers successfully develop and maintain connected products.”
Digi ConnectCore MP1 SOMs are distinct from other SOMs in that they offer comprehensive, fully-integrated solutions, which include a range of development tools, design support, wireless connectivity options, software and security features. These solutions include access to Digi ConnectCore Cloud Services and Digi ConnectCore Security Services, which aid in streamlining deployment, device management and ongoing maintenance across the product's entire lifecycle.
Digi ConnectCore MP13 Features
- STM32MP13x, single Cortex-A7 @ 650 MHz
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.2 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework — ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“With the launch of Digi ConnectCore MP13, Digi has created pin-compatible family of SOMs to support the ST Microelectronics STM32MP1 microprocessors,” said Dan Kobylarz, Senior Director of Engineering, OEM Solutions Group at Digi. “The ConnectCore MP13 is ideal for the rapid development of cost-effective gateways for Smart City and Energy applications, while the ConnectCore MP15 supports connected devices with HMI requirements. With the ConnectCore MP1 SOM family, a customer gets the best of both worlds.”
For more information, visit https://www.digi.com/products/embedded-systems/digi-connectcore/system-on-modules/digi-connectcore-mp1.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit https://www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005132/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom